453 related articles for article (PubMed ID: 21116000)
1. Mammalian target of rapamycin: biological function and target for novel anticancer agents.
Borders EB; Bivona C; Medina PJ
Am J Health Syst Pharm; 2010 Dec; 67(24):2095-106. PubMed ID: 21116000
[TBL] [Abstract][Full Text] [Related]
2. Targeting mTOR pathways in human malignancies.
Fasolo A; Sessa C
Curr Pharm Des; 2012; 18(19):2766-77. PubMed ID: 22475451
[TBL] [Abstract][Full Text] [Related]
3. Everolimus: side effect profile and management of toxicities in breast cancer.
Paplomata E; Zelnak A; O'Regan R
Breast Cancer Res Treat; 2013 Aug; 140(3):453-62. PubMed ID: 23907751
[TBL] [Abstract][Full Text] [Related]
4. Hematologic toxicities associated with mTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis.
Xu J; Tian D
Curr Med Res Opin; 2014 Jan; 30(1):67-74. PubMed ID: 24028709
[TBL] [Abstract][Full Text] [Related]
5. Everolimus for the treatment of advanced renal cell carcinoma.
Amato R
Expert Opin Pharmacother; 2011 May; 12(7):1143-55. PubMed ID: 21470068
[TBL] [Abstract][Full Text] [Related]
6. Current and future directions in mammalian target of rapamycin inhibitors development.
Fasolo A; Sessa C
Expert Opin Investig Drugs; 2011 Mar; 20(3):381-94. PubMed ID: 21299441
[TBL] [Abstract][Full Text] [Related]
7. Oral stomatitis and mTOR inhibitors: A review of current evidence in 20,915 patients.
Lo Muzio L; Arena C; Troiano G; Villa A
Oral Dis; 2018 Mar; 24(1-2):144-171. PubMed ID: 29480626
[TBL] [Abstract][Full Text] [Related]
8. mTOR signaling and drug development in cancer.
Dancey J
Nat Rev Clin Oncol; 2010 Apr; 7(4):209-19. PubMed ID: 20234352
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of everolimus in renal cell cancer.
Amato R; Stepankiw M
Expert Opin Pharmacother; 2013 Jun; 14(9):1229-40. PubMed ID: 23578333
[TBL] [Abstract][Full Text] [Related]
10. Everolimus.
Hasskarl J
Recent Results Cancer Res; 2018; 211():101-123. PubMed ID: 30069763
[TBL] [Abstract][Full Text] [Related]
11. Everolimus in renal cell carcinoma.
Wang Y
Drugs Today (Barc); 2010 Aug; 46(8):557-66. PubMed ID: 20830316
[TBL] [Abstract][Full Text] [Related]
12. Common toxicities of mammalian target of rapamycin inhibitors.
Soefje SA; Karnad A; Brenner AJ
Target Oncol; 2011 Jun; 6(2):125-9. PubMed ID: 21499766
[TBL] [Abstract][Full Text] [Related]
13. Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
Serova M; de Gramont A; Tijeras-Raballand A; Dos Santos C; Riveiro ME; Slimane K; Faivre S; Raymond E
Cancer Chemother Pharmacol; 2013 May; 71(5):1297-307. PubMed ID: 23479136
[TBL] [Abstract][Full Text] [Related]
14. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
Chan HY; Grossman AB; Bukowski RM
Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
[TBL] [Abstract][Full Text] [Related]
15. The applicability of mTOR inhibition in solid tumors.
Konings IR; Verweij J; Wiemer EA; Sleijfer S
Curr Cancer Drug Targets; 2009 May; 9(3):439-50. PubMed ID: 19442061
[TBL] [Abstract][Full Text] [Related]
16. Temsirolimus: a safety and efficacy review.
Bukowski RM
Expert Opin Drug Saf; 2012 Sep; 11(5):861-79. PubMed ID: 22861825
[TBL] [Abstract][Full Text] [Related]
17. Everolimus.
Hasskarl J
Recent Results Cancer Res; 2014; 201():373-92. PubMed ID: 24756805
[TBL] [Abstract][Full Text] [Related]
18. Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes.
Atkinson BJ; Cauley DH; Ng C; Millikan RE; Xiao L; Corn P; Jonasch E; Tannir NM
BJU Int; 2014 Mar; 113(3):376-82. PubMed ID: 24053120
[TBL] [Abstract][Full Text] [Related]
19. Differentiating mTOR inhibitors in renal cell carcinoma.
Pal SK; Quinn DI
Cancer Treat Rev; 2013 Nov; 39(7):709-19. PubMed ID: 23433636
[TBL] [Abstract][Full Text] [Related]
20. Everolimus: a new treatment option for advanced pancreatic neuroendocrine tumors.
Thompson LA; Kim M; Wenger SD; O'Bryant CL
Ann Pharmacother; 2012 Sep; 46(9):1212-9. PubMed ID: 22947595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]